CD86 and central nervous system cancer: Figure 4G shows the risk plot in TCGA glioma cohort, including the distribution of risk score and accurate classification of survival outcomes across different risk groups with red dots being dead and blue ones being living cases. The expression levels of four hub genes demonstrated a trend of upregulation of ANXA1 along with downregulation of CD86, C5AR1, and CD5 in the high-risk group as classified by the PROMISE model (Figure 4G).